Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Does long term use of 5 alpha reductase inhibitors change the way you evaluate a PSMA PET?
Related Questions
How do you manage malignancies in patients with Birt-Hogg-Dubé syndrome (BHD)? Is there concern for increased radiosensitivity?
Do you offer prostate RT to men with 0-3 bone metastases on conventional imaging when PSMA PET shows a very high number of M1 lesions?
What is your preferred dose to gross lymph nodes when treating non-metastatic high-risk prostate cancer?
Do you ever dose escalate radiotherapy to the primary in low volume metastatic prostate cancer?
What radiation treatments would you offer an older man with unfavorable intermediate-risk prostate cancer, with comorbid conditions, if you don't feel he is a good candidate for full-course radiation therapy with ADT?
How do you manage LUTS in the post-prostatectomy setting?
Would you treat a patient with evidence of prostate cancer who refuses biopsy?
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
For recurrent prostate cancer after prostatectomy with soft tissue mass in the prostate fossa, is hypofractionation an option or is standard fractionation recommended?
